BioCentury
ARTICLE | Clinical News

Vertex discontinues development of spinal cord injury compound VX-210

October 26, 2018 9:21 PM UTC

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) discontinued development of acute spinal cord injury candidate VX-210 after a DSMB recommended stopping a Phase IIb trial for futility following an interim analysis.

Vertex has rights to VX-210 from BioAxone BioSciences Inc. (Cambridge, Mass.) under a 2014 deal in which BioAxone received an upfront payment of $10 million and was eligible for up to $90 million in milestones, plus royalties...